BMS Archive

Plant · Scientific monograph

Passiflora incarnata

Passionflower / Maypop

For educational and scientific research only. Not medical advice. Independently verify claims against the cited primary sources. Consult a qualified healthcare professional before using any plant or fungal preparation.

Research areas: Stress & Anxiety Research, CNS Depression Research, GABAergic, Sleep Research

Research overview

Historical use

Passiflora incarnata (Maypop) is native to the southeastern United States and Central America, where it was used by indigenous peoples including the Cherokee and Aztecs as a sedative, analgesic, and antispasmodic. Spanish explorers introduced it to Europe in the 16th century; it was official in the US National Formulary from 1916 to 1936 and remains listed in the pharmacopoeias of France, Germany, and the UK.

Modern research context

Passionflower has a strong and growing clinical evidence base for anxiety and sleep disorders. A randomised double-blind placebo-controlled clinical trial demonstrates statistically significant reduction in stress and improvement in sleep quality with no adverse effects [8]. Multiple RCTs confirm anxiolytic efficacy in procedural anxiety during dental surgery [2, 4] — with performance comparable to traditional anxiolytics but fewer side effects [3]. Real-world clinical data support passionflower as an effective add-on during benzodiazepine tapering, with documented long-term safety and efficacy [6].

Adverse effects

Generally well tolerated in clinical trials with no adverse events reported in the 2024 stress/sleep RCT [8]. Drowsiness and sedation are the most common dose-dependent effects. Rare: dizziness, confusion, vasculitis. Potential for serotonin syndrome when combined with serotonergic medications [1]. Risk of additive CNS depression with concomitant sedatives or alcohol.

Contraindications

Contraindicated with MAO inhibitors due to harman alkaloid content (MAO inhibition). Avoid with other CNS depressants without dose adjustment due to additive sedation [1]. Caution with anticoagulants — flavonoids may inhibit platelet aggregation. Avoid concurrent use with SSRIs/SNRIs due to serotonin syndrome risk [1]. Do not use during pregnancy (uterotonic alkaloids). Do not use before driving or operating machinery.

Clinical and phytochemical data

Used part

Aerial parts (leaves, stems, tendrils, flowers) — dried or as hydroethanolic extract

Primary active compounds

  • Chrysin (flavone — primary anxiolytic)

  • Vitexin and isovitexin (C-glycosyl flavones)

  • Orientin and isoorientin

  • Harman, harmol, harmalol (beta-carboline alkaloids — MAO inhibition)

  • Passiflorine (alkaloid)

  • Edulilic acid

Mechanism of action

Chrysin, the principal flavone, binds to the benzodiazepine site of the GABA-A receptor, potentiating chloride ion influx and producing anxiolytic and sedative effects comparable to low-dose benzodiazepines [3]. The beta-carboline alkaloids (harman, harmol) reversibly inhibit monoamine oxidase A (MAO-A), elevating synaptic monoamine concentrations and contributing to antidepressant and anxiolytic effects [1]. Passiflora incarnata extract modulates cytochrome P450 enzyme activity, with documented risk of herb-drug interactions via this pathway [1]. Anti-inflammatory effects are mediated through inhibition of NF-κB and COX-2 pathways; hepatoprotective properties are documented in preclinical models [7].

Pharmacokinetics

Absorption

No human pharmacokinetic data are available for this species. The following is derived from preclinical animal studies and in vitro data only, and may not reflect human pharmacology. — Chrysin has poor oral bioavailability due to rapid phase II conjugation (glucuronidation and sulfation) and efflux by intestinal P-glycoprotein. C-glycosyl flavones (vitexin, isovitexin) require microbial deglycosylation in the large intestine prior to systemic absorption.

Distribution

No human pharmacokinetic data are available for this species. The following is derived from preclinical animal studies and in vitro data only, and may not reflect human pharmacology. — Chrysin and its metabolites distribute to CNS in preclinical models, consistent with the documented central anxiolytic and sedative effects [3, 8]. Protein binding of chrysin is high (>99%) in animal studies.

Metabolism

No human pharmacokinetic data are available for this species. The following is derived from preclinical animal studies and in vitro data only, and may not reflect human pharmacology. — Chrysin undergoes rapid sulfation and glucuronidation by intestinal and hepatic phase II enzymes. Passiflora extracts interact with CYP450 enzymes with potential clinical consequences for co-administered drugs [1]. The beta-carboline alkaloids are substrates of MAO enzymes, contributing to mutual inhibition.

Excretion

No human pharmacokinetic data are available for this species. The following is derived from preclinical animal studies and in vitro data only, and may not reflect human pharmacology. — Chrysin conjugates are primarily renally excreted. Half-life and systemic elimination kinetics of the primary flavones in humans have not been characterised in formal pharmacokinetic studies.

Safety and interactions

Drug interactions

CNS depressants (benzodiazepines, opioids, alcohol): Additive sedation through shared GABAergic mechanism; the combination has been used clinically during benzodiazepine tapering without serious adverse events reported in the cited real-world study [6], but requires medical supervision. MAO inhibitors: Harman alkaloids inhibit MAO-A; combination with MAOI antidepressants is contraindicated due to risk of hypertensive crisis and serotonin syndrome [1]. SSRIs/SNRIs: Serotonin syndrome risk documented when combined with serotonergic agents [1]; monitor closely. CYP450 substrates: Herb-drug interactions via CYP450 modulation are a documented class risk [1].

Toxicity

No serious adverse events reported in multiple RCTs [8, 4]. The 2024 benzodiazepine tapering real-world study confirmed long-term safety over extended treatment periods [6]. Harman alkaloids in high doses carry theoretical MAO inhibition risk. No hepatotoxicity data in clinical use. LD50 in humans is not established.

Special precautions

Pregnancy

Uterotonic alkaloids present. Contraindicated during pregnancy.

Lactation

Alkaloid excretion into breast milk not characterised. Avoid during lactation.

Hepatic impairment

Hepatoprotective effects documented preclinically [7]. CYP450 interactions may be altered in hepatic disease [1]. Use with caution and monitor drug levels of co-administered medications.

Renal impairment

No formal studies. Flavonoid conjugates renally excreted. Use with caution in severe renal impairment.

Sources and references

  1. [1] - Caus MN, Lupoae M, Chitescu CL, "Efficacy and Safety of Herbal Supplements with Anxiolytic, Antidepressant, and Sedative Action", Pharmaceuticals, 2026, PMID: 41901246
  2. [2] - Lima Neto TJ, Ribeiro NP, Souza MB et al., "Effects of Passiflora incarnata on salivary biomarkers and anxiety in patients undergoing third molar extraction surgery", Scientific Reports, 2025, PMID: 41381570
  3. [3] - Kafas P, Lillis T, Dabarakis N, "Anxiolytic Potential of Passiflora incarnata in Oral Surgery: Mechanisms, Evidence and Clinical Application", Pakistan Journal of Biological Sciences, 2025, PMID: 41392563
  4. [4] - Velasquez ACA, Tsuji M, Dos Santos Cordeiro L et al., "Effects of Passiflora incarnata and Valeriana officinalis in the control of anxiety due to tooth extraction: a randomized controlled clinical trial", Oral and Maxillofacial Surgery, 2024, PMID: 38743126
  5. [5] - Zampieri VC, Goncalves IL, Lira AL et al., "Exploring the Effects of a Calming Herbal Tea Blend on Perioperative Anxiety: A Randomized Clinical Trial", Journal of Medicinal Food, 2025, PMID: 39514279
  6. [6] - Carminati M, Tondello M, Zanardi R, "Passiflora incarnata L. in benzodiazepine tapering: long-term safety and efficacy in a real-world setting", Frontiers in Psychiatry, 2024, PMID: 39429529
  7. [7] - Nikolova K, Velikova M, Gentscheva G et al., "Chemical Compositions, Pharmacological Properties and Medicinal Effects of Genus Passiflora L.: A Review", Plants, 2024, PMID: 38256781
  8. [8] - Harit MK, Mundhe N, Tamoli S et al., "Randomized, Double-Blind, Placebo-Controlled, Clinical Study of Passiflora incarnata in Participants With Stress and Sleep Problems", Cureus, 2024, PMID: 38646244

Additional source links

Continue browsing